Study of AMG 650 in Adult Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

October 24, 2022

Study Completion Date

February 15, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

AMG 650

AMG 650 administered orally as a tablet.

Trial Locations (22)

3000

Peter MacCallum Cancer Centre, Melbourne

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven

5011

The Queen Elizabeth Hospital, Woodville South

10016

Laura and Isaac Perlmutter Cancer Center at New York University Langone, New York

14263

Roswell Park Cancer Institute, Buffalo

20141

IRCCS Istituto Europeo di Oncologia, Milan

27157

Wake Forest University School of Medicine, Winston-Salem

28009

Hospital General Universitario Gregorio Marañon, Madrid

37203

Sarah Cannon Research Institute, Nashville

46202

Indiana University, Indianapolis

55905

Mayo Clinic, Rochester

73104

Stephenson Cancer Center, Oklahoma City

75246

Texas Oncology - Baylor, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

90025

The Angeles Clinic and Research Institute, West Los Angeles Office, Los Angeles

90403

Sarcoma Oncology Research Center LLC, Santa Monica

97239

Oregon Health and Science University, Portland

63110-1093

Washington University, St Louis

T6G 1Z2

Cross Cancer Institute, Edmonton

M5G 1Z5

Princess Margaret Cancer Centre, Toronto

464-8681

Aichi Cancer Center, Nagoya

277-8577

National Cancer Center Hospital East, Kashiwa-shi

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Volastra Therapeutics, Inc.

INDUSTRY

NCT04293094 - Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter